Penn Medicine to Launch New Brain Tumor Center
The $35 million facility in Philadelphia will focus on developing targeted immunotherapies for aggressive brain cancers.
Updated on Oct. 29, 2026 in Cancer
Live Poll
Should medical institutions prioritize funding for new research centers to develop treatments for aggressive cancers?
Penn Medicine announced on October 29, 2026, that it is establishing the Troiano Brain Tumor Center. The research facility is expected to officially launch in mid-November 2026.
Why it matters
The center aims to overcome the challenges posed by brain tumors, which are known to evade the immune system and possess diverse biological traits that complicate standard treatment. By translating scientific discoveries into clinical practice, the facility seeks to improve outcomes for patients battling aggressive forms of the disease.
The new research center is supported by $35 million in philanthropic and institutional funding. Staffing plans include nearly 100 individuals dedicated to investigating genetic mutations and immunotherapy development.
The players
Nduka Amankulor
He will serve as the executive director for the newly established Troiano Brain Tumor Center at Penn Medicine.
Stephen Bagley
He is set to lead the clinical operations for the center as the appointed clinical director.
Penn Medicine
This Philadelphia-based academic medical center is the institution housing the new brain cancer research initiative.
The details
Researchers at the center will identify specific genetic mutations within tumors to guide the creation of targeted therapies. The facility will prioritize the development of CAR-T immunotherapies and RNA-based treatments designed to reactivate the immune system against cancer cells.
Timeline
October 29, 2026: The research center was formally announced.
Mid-November 2026: The Troiano Brain Tumor Center is scheduled to officially launch.
Health Landscape
The center extends the research goals of the National Cancer Institute's Cancer Moonshot initiative by focusing on the rapid translation of lab science into clinical care. This move highlights a broader shift toward specialized, immune-focused therapies for cancers that have historically evaded traditional treatments.
The new center offers potential future treatment options for individuals diagnosed with aggressive brain tumors like glioblastoma. Patients and families may benefit from the facility's focus on experimental CAR-T and RNA-based therapies as these reach clinical trial stages.
The takeaway
The establishment of this center reflects an increasing reliance on targeted genetic and immune-based research to combat difficult-to-treat diseases. Patients should monitor clinical trial registries for updates on when these therapies move from research to human testing.
What happens next
The Troiano Brain Tumor Center is scheduled to hold its official launch in mid-November 2026.
Further reading
For more on local oncology research and advancements, visit Philadelphia Cancer.
Source note: This article includes information reported by The Philadelphia Inquirer.
Live Poll
Should medical institutions prioritize funding for new research centers to develop treatments for aggressive cancers?
